Bausch Health Companies Inc. Stock News

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have closed the upsized offering of €675 million aggregate pri...

We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.

John Paulson, former hedge-fund manager, bought large blocks of Bausch Health and Perpetua Resources through funds.

In the past week or so, a couple of gold-mining stocks attracted the attention of insider buyers.

Bausch Health shares rose Wednesday morning after a director made a substantial purchase of company stocks.

Bausch Health is significantly undervalued, trading at depressed multiples due to high debt and patent risk, but its core business remains stable and cash generative. Recent refinancing has extended debt maturities past 2027, giving management time to monetize assets and reduce leverage before Xifaxan's patent expires in 2028. Despite risks—$21.5B debt, Xifaxan patent cliff, and regulatory unce...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort f...

The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appearance and the popularity of minimally invasive procedures fuel demand, while the Asia-Pacific region sees rapid expansion due to urbanization and rising incomes. Key players like Allergan and Galder...